These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 2359515)

  • 1. Complement-activated oligodendroglia: a new pathogenic entity identified by immunostaining with antibodies to human complement proteins C3d and C4d.
    Yamada T; Akiyama H; McGeer PL
    Neurosci Lett; 1990 May; 112(2-3):161-6. PubMed ID: 2359515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complement activated C4d immunoreactive oligodendrocytes delineate small cortical plaques in multiple sclerosis.
    Schwab C; McGeer PL
    Exp Neurol; 2002 Mar; 174(1):81-8. PubMed ID: 11869036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of the classical complement pathway in brain tissue of Alzheimer patients.
    McGeer PL; Akiyama H; Itagaki S; McGeer EG
    Neurosci Lett; 1989 Dec; 107(1-3):341-6. PubMed ID: 2559373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement deposition in early cardiac transplant biopsies is associated with ischemic injury and subsequent rejection episodes.
    Baldwin WM; Samaniego-Picota M; Kasper EK; Clark AM; Czader M; Rohde C; Zachary AA; Sanfilippo F; Hruban RH
    Transplantation; 1999 Sep; 68(6):894-900. PubMed ID: 10515392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of C3d and C4d immunohistochemistry on formalin-fixed tissue as a diagnostic adjunct in the assessment of inflammatory skin disease.
    Magro CM; Dyrsen ME
    J Am Acad Dermatol; 2008 Nov; 59(5):822-33. PubMed ID: 19119098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterogeneity of C4d and C3d and their complex formation with serum albumin.
    Petersen NE; Teisner B; Folkersen J; Svehag SE
    Acta Pathol Microbiol Immunol Scand C; 1987 Aug; 95(4):129-35. PubMed ID: 3499750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reflection of disease activity in rheumatoid arthritis by indices of activation of the classical complement pathway.
    Makinde VA; Senaldi G; Jawad AS; Berry H; Vergani D
    Ann Rheum Dis; 1989 Apr; 48(4):302-6. PubMed ID: 2785367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Immunohistochemical appearance of complement protein, C4d, in the nervous system and its significance].
    Yamada T
    No To Shinkei; 1998 Feb; 50(2):137-45. PubMed ID: 9513203
    [No Abstract]   [Full Text] [Related]  

  • 9. Classical pathway complement activation in Kawasaki syndrome.
    Kohsaka T; Abe J; Asahina T; Kobayashi N
    J Allergy Clin Immunol; 1994 Feb; 93(2):520-5. PubMed ID: 8120278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pathology of multiple sclerosis is location-dependent: no significant complement activation is detected in purely cortical lesions.
    Brink BP; Veerhuis R; Breij EC; van der Valk P; Dijkstra CD; Bö L
    J Neuropathol Exp Neurol; 2005 Feb; 64(2):147-55. PubMed ID: 15751229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of in vivo immune complex formation and complement activation in patients receiving intravenous streptokinase.
    Freysdottir J; Ormarsdottir S; Sigfusson A
    Clin Exp Immunol; 1993 Nov; 94(2):286-90. PubMed ID: 8222319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo instability of red-blood-cell-bound C3d and C4d.
    Chaplin H; Coleman ME; Monroe MC
    Blood; 1983 Nov; 62(5):965-71. PubMed ID: 6605168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complement activation reaches maximum during equilibrium between antigen and antibody in an in vitro model for thrombolysis with streptokinase.
    Leinøe E; Pachaï A; Brandslund I
    APMIS; 2000 Oct; 108(10):685-8. PubMed ID: 11200823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A flow cytometric assay for measuring complement receptor 1 (CR1) and the complement fragments C3d and C4d on erythrocytes.
    Freysdottir J; Sigfusson A
    J Immunol Methods; 1991 Aug; 142(1):45-52. PubMed ID: 1833467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of the complement system in primary sclerosing cholangitis.
    Senaldi G; Donaldson PT; Magrin S; Farrant JM; Alexander GJ; Vergani D; Williams R
    Gastroenterology; 1989 Dec; 97(6):1430-4. PubMed ID: 2583409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of the activation of the fourth component of complement (C4) with disease activity in systemic lupus erythematosus.
    Senaldi G; Makinde VA; Vergani D; Isenberg DA
    Ann Rheum Dis; 1988 Nov; 47(11):913-7. PubMed ID: 3264693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of the complement system in human immunodeficiency virus infection: relevance of the classical pathway to pathogenesis and disease severity.
    Senaldi G; Peakman M; McManus T; Davies ET; Tee DE; Vergani D
    J Infect Dis; 1990 Dec; 162(6):1227-32. PubMed ID: 1977807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of early components of complement targets myelin and oligodendrocytes in the aged rhesus monkey brain.
    Duce JA; Hollander W; Jaffe R; Abraham CR
    Neurobiol Aging; 2006 Apr; 27(4):633-44. PubMed ID: 15992964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of complement activation products in Chinese patients with systemic lupus erythematosus.
    Li J; An L; Zhang Z
    Clin Exp Rheumatol; 2014; 32(1):48-53. PubMed ID: 23981509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased concentration of C4d complement protein in the cerebrospinal fluids in progressive supranuclear palsy.
    Yamada T; Moroo I; Koguchi Y; Asahina M; Hirayama K
    Acta Neurol Scand; 1994 Jan; 89(1):42-6. PubMed ID: 8178627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.